Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

Stock Information for Tevogen Bio Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tevogen Bio Holdings Inc.

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell-Based Therapies with 100x PredicTcell(TM) Beta Data Expansion
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.